Korelasi Tingkat Keparahan Efek Samping Obat Regimen Leucovorin Calcium (Folinic Acid), Fluorouracil, dan Oxaliplatin dengan Kualitas Hidup Pasien Kanker Kolorektal
Abstract
Adanya kejadian efek samping obat (ESO) pada pasien kemoterapi dapat memberikan resiko pada penurunan kualitas hidup. Penelitian ini bertujuan untuk mengetahui korelasi tingkat keparahan efek samping obat regimen leucovorin calcium (folinic acid), fluorouracil, dan oxaliplatin (FOLFOX) dengan kualitas hidup pasien kanker kolorektal. Jenis penelitian yang digunakan adalah observasional dengan rancangan studi cross sectional dan pengambilan data secara prospektif tahun 2020-2021 di 3 rumah sakit yaitu RSUP X, RSUD X dan RSUD Y Cirebon. Data yang diambil berupa kejadian efek samping obat baik jenis dan jumlahnya, tingkat keparahan efek samping serta tingkat kualitas hidup. Instrumen yang digunakan adalah Hartwigh et. al. dan kuesioner EORTC QLQ c-30 versi 3 dalam Bahasa Indonesia. Analisis korelasi dengan Pearson Correlation. Jumlah sampel yang didapatkan sebanyak 43 pasien. Jenis ESO yang paling banyak adalah mual, sedangkan yang paling parah stomatitis dan muntah. Skor kualitas hidup pasien yang mengalami ESO yaitu kualitas hidup global 66,26, kualitas hidup fungsional 71,98 dan kualitas hidup gejala 31,29. Korelasi antara tingkat keparahan efek samping obat dengan kualitas hidup domain global sebesar -0,421, kualitas hidup domain fungsional sebesar -0,638, dan kualitas hidup domain gejala sebesar 0,722. Tingkat keparahan efek samping obat berkorelasi dengan kualitas hidup pasien. Identifikasi efek samping obat dan tingkat keparahannya sejak dini tentu dapat mencegah penurunan kualitas hidup pasien.
Keywords
Full Text:
PDF (Bahasa Indonesia)References
American Cancer Society. Colorectal Cancer Facts & Figures 2017-2019. Am Cancer Soc. 2017;
Kemenkes RI. HASIL UTAMA RISKESDAS 2018. Jakarta: Kementerian Kesehatan RI; 2018.
Kemenkes RI. KEPUTUSAN MENTERI KESEHATAN REPUBLIK INDONESIA NOMOR HK.01.07/MENKES/406/2018 TENTANG PEDOMAN NASIONAL PELAYANAN KEDOKTERAN TATA LAKSANA KANKER KOLOREKTAL. Jakarta: Kementerian Kesehatan RI; 2018. 1–160 p.
Lim H, Kim SY, Lee E, Lee S, Oh S, Jung J, et al. Sex-dependent adverse drug reactions to 5-fluorouracil in colorectal cancer. Biol Pharm Bull. 2019;42(4):594–600.
BPOM RI. FARMAKOVIGILANS (KEAMANAN OBAT) PANDUAN DETEKSI DAN PELAPORAN EFEK SAMPING OBAT UNTUK TENAGA KESEHATAN. Jakarta: Pusat Farmakovigilans/MESO Nasional, Badan Pengawas Obat dan Makanan; 2019.
Marventano S, Forjaz MJ, Grosso G, Mistretta A, Giorgianni G, Platania A, et al. Health related quality of life in colorectal cancer patients: State of the art. BMC Surg [Internet]. 2013;13(SUPPL.2):S15. Available from: http://www.biomedcentral.com/1471-2482/13/S2/S15
Polat U, Arpacı A, Demir S, Erdal S, Yalcin Ş. Evaluation of quality of life and anxiety and depression levels in patients receiving chemotherapy for colorectal cancer : impact of patient education before treatment initiation. 2014;5(4):270–5.
Ratjen I, Schafmayer C, Enderle J, Di Giuseppe R, Waniek S, Koch M, et al. Health-related quality of life in long-term survivors of colorectal cancer and its association with all-cause mortality: A German cohort study. BMC Cancer. 2018;18(1):1–15.
Saleh A, Kaelan C. DEPRESI BERHUBUNGAN DENGAN KUALITAS HIDUP PENDERITA Pendahuluan. 2019;22(October 2018):83–91.
Perwitasari DA. Development the Validation of Indonesian Version of Sf-36 Questionnaire in Cancer Disease. Indones J Pharm. 2012;23(4):248–53.
BPOM RIa. PHARMACOVIGILANCE MODULE FOR HEALTH PROFESSIONALS. Jakarta: BPOM RI; 2020.
Susilo R. Translation and Validation of the Indonesian Version of the Adverse Drug Reaction Severity Level Instruments in Colorectal Cancer Patients. J Multidiscip Healthc [Internet]. 2022;(May):1153–61. Available from: https://www.dovepress.com/translation-and-validation-of-the-indonesian-version-of-the-adverse-dr-peer-reviewed-fulltext-article-JMDH
Sugiyono. Statistika Untuk Penelitian. Bandung: Bandung: Alfabeta; 2010.
Steven C Hartwig, Jerry Siegel APJS. Preventability and Severity Assessment in Reporting Adverse Drug Reactions. 2014;(October 1992).
Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. Vol. 14, Przeglad Gastroenterologiczny. Termedia Publishing House Ltd.; 2019. p. 89–103.
Provenzale D, Gupta S, Ahnen DJ, Markowitz AJ, Chung DC, Mayer RJ, et al. NCCN Guidelines(r) insights colorectal cancer screening, version 1.2018 featured updates to the NCCN guidelines. Vol. 16, JNCCN Journal of the National Comprehensive Cancer Network. Harborside Press; 2018. p. 939–49.
Provenzale D, Ness RM, Llor X, Weiss JM, Abbadessa B, Cooper G, et al. Colorectal cancer screening, version 2.2020 featured updates to the NCCN guidelines. JNCCN J Natl Compr Cancer Netw. 2020 Oct 1;18(10):1312–20.
He J, Cheng J, Guan Q, Yan H, Li Y, Zhao W, et al. Qualitative transcriptional signature for predicting pathological response of colorectal cancer to FOLFOX therapy. Cancer Sci. 2020 Jan 1;111(1):253–65.
Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, et al. Colorectal cancer. Nat Rev Dis Prim. 2015 Nov 5;1.
Mauri G, Sartore-Bianchi A, Russo AG, Marsoni S, Bardelli A, Siena S. Early-onset colorectal cancer in young individuals. Vol. 13, Molecular Oncology. John Wiley and Sons Ltd; 2019. p. 109–31.
Qin S, Li J, Wang L, Xu J, Cheng Y, Bai Y, et al. JOURNAL OF CLINICAL ONCOLOGY Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial. J Clin Oncol [Internet]. 2018;36:3031–9. Available from: https://doi.org/10.1200/JCO.2018.
Machida N, Yoshizaki K, Boku N, Yamazaki K, Onozawa Y, Fukutomi A, et al. Feasibility of mFOLFOX6 as the adjuvant treatment after curative resection of metastases from colorectal cancer in Japanese patients. Int J Clin Oncol. 2013;18(2):279–84.
Malka D, François E, Penault-Llorca F, Castan F, Bouché O, Bennouna J, et al. FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. Eur J Cancer. 2019;115:97–106.
Salehifar E, Gheibi S, Janbabaei G, Mousavi K. Adverse Effects of Chemotherapy Regimens Used in Colorectal Cancer Patients in a Referral Cancer Center in North of Iran, 2008-2014. 2016.
Salehifar E, Avan R, Janbabaei G, Mousavi SK, Faramarzi F. Comparison the incidence and severity of side effects profile of folfox and dcf regimens in gastric cancer patients. Iran J Pharm Res. 2019;18(2):1032–9.
Flyum IR, Mahic S, Grov EK, Joranger P. Health-related quality of life in patients with colorectal cancer in the palliative phase: a systematic review and meta-analysis. BMC Palliat Care. 2021 Dec 1;20(1).
Sánchez-Gundín J, Fernández-Carballido AM, Torres-Suárez AI, Barreda-Hernández D. Quality of life in non-metastasic colorectal cancer patients in Folfox or Xelox therapy. Farm Hosp. 2019 Mar 1;43(2):56–60.
Hsu HT, Wu LM, Lin PC, Juan CH, Huang YY, Chou PL, et al. Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: A cross-sectional study. Med (United States). 2020;99(6).
Lee SH, Lee T-G, Baek MJ, Kim JJ, Park S-S, Lee S-J. Quality of life changes during adjuvant chemotherapy in patients with colon cancer. Korean J Clin Oncol. 2016 Jun 30;12(1):60–6.
Akhondi-Meybodi M, Akhondi-Meybodi S, Vakili M, Javaheri Z. Quality of life in patients with colorectal cancer in Iran. Arab J Gastroenterol. 2016 Sep 1;17(3):127–30.
NIH. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. J Chem Soc Dalt Trans. 2017;
DOI: https://doi.org/10.15416/ijcp.2022.11.3.225
Refbacks
- There are currently no refbacks.
Indonesian Journal of Clinical Pharmacy is indexed by
